Efficacy and Tolerability Evaluation of a Topical MD Based on SHBF in Management of Radiodermatitis.

Inclusion Criteria: * Women who give their written consent for participation in the study and willing to comply with all its procedures. * Age ≥18 years. * Women with breast cancer at any stage who have undergone quadrantectomy, for whom hypofractionated adjuvant RT of the thoracic region is indicated. * RTOG/ EORTC radiodermatitis grade equal to 0 (zero) and good cutaneous trophism, in the region to be treated, according to investigator's judgement. * Patients who are supposed to be cooperative with regard to compliance with study-related constraints. Exclusion Criteria: * Pregnant or lactating women (as not eligible to RT), and fertile women not following, at the investigators' judgement, an adequate contraceptive method. * Subjects incapable of giving consent. * Concomitant inflammatory skin diseases in acute phase such as: atopic dermatitis, contact dermatitis, psoriasis, lichen planus, pityriasis rosea. * Collagen vascular disease, vasculitis, scleroderma, dermatomyositis, or systemic lupus erythematosus. * Unhealed surgical sites, breast infections. * Bilateral breast cancer or multiple neoplasia needing other independent RT treatments. * Prior breast reconstructions, implants, and/or expanders. * Known radio-sensitivity syndromes (e.g. ataxia-telangiectasia). * Known history of intolerance or hypersensitivity to any ingredient of the study products. * Previous RT in the same or different location. * Topical pharmacological and medical device treatments on the skin r…